How should AVAPS (average volume‑assured pressure support) be indicated, initially set, and monitored in patients with chronic hypercapnic respiratory failure such as COPD, obesity‑hypoventilation syndrome, or neuromuscular weakness?

AVAPS in Chronic Hypercapnic Respiratory Failure

AVAPS (Average Volume-Assured Pressure Support) is an acceptable mode of noninvasive ventilation for chronic hypercapnic respiratory failure, with recommended initial settings of EPAP 4 cm H₂O, IPAP min = EPAP + 4 cm H₂O, IPAP max 25-30 cm H₂O, and target tidal volume of 8 mL/kg ideal body weight. 1

Indications for AVAPS

AVAPS should be considered in patients with:

• Chronic hypercapnic respiratory failure from COPD, obesity-hypoventilation syndrome (OHS), neuromuscular disease, or restrictive chest wall disorders
• Variable respiratory drive or muscle strength where automatic pressure adjustment provides advantage over fixed bilevel pressure support 1
• Failure to maintain adequate tidal volumes on standard bilevel pressure support

The key advantage is automatic adjustment of inspiratory pressure to maintain target tidal volume when respiratory muscle strength declines or ventilatory demands change 1.

Initial Settings

Start with these parameters 1:

• EPAP: 4 cm H₂O (increase to 8-10 cm H₂O if concurrent obstructive sleep apnea)
• IPAP min: 8 cm H₂O (EPAP + 4 cm H₂O minimum pressure support)
• IPAP max: 25-30 cm H₂O (20 cm H₂O maximum for patients <12 years)
• Target tidal volume: 8 mL/kg ideal body weight (acceptable range 6-8 mL/kg)

Mode selection:

• Use spontaneous-timed (ST) mode with backup rate for patients with central apneas, inappropriately low respiratory rate, or unreliable triggering due to muscle weakness 1
• Set backup rate at 2-4 breaths below spontaneous rate (typically 12-16 breaths/minute) 2
• Set inspiratory time to achieve I:E ratio of 1:2 minimum; use longer expiratory time in COPD (lower %IPAP time), shorter in restrictive disease 1

Titration and Monitoring

During initial polysomnography titration 1:

Adjust EPAP first to eliminate obstructive events (apneas, hypopneas, RERAs, snoring) following standard OSA titration protocols 1.

Monitor that AVAPS delivers adequate pressure support by assessing:

• Tidal volume: Should achieve 6-8 mL/kg; if consistently low despite IPAP max being reached, increase IPAP max in 2 cm H₂O increments 1
• PCO₂ reduction: Goal is PCO₂ ≤ awake value; increase target tidal volume if PCO₂ remains ≥10 mmHg above goal for >10 minutes 1
• SpO₂: Maintain ≥90%; if persistently <90% for >5 minutes with low tidal volume, increase target tidal volume 1
• Respiratory muscle rest: Resolution of tachypnea and excessive inspiratory effort 1

Critical pitfall: Excessive leak degrades flow signal accuracy and tidal volume estimates. If increasing IPAP max fails to improve tidal volume, suspect and address mask leak before further adjustments 1.

Long-term Follow-up

Reassess at 1 month, then every 3-6 months 2:

• Arterial or transcutaneous PCO₂ measurement
• Download ventilator data: adherence, leak, tidal volumes, pressures delivered
• Symptom assessment (dyspnea, morning headaches, daytime sleepiness)
• Consider repeat polysomnography if persistent symptoms or inadequate gas exchange improvement

Adjust settings if:

• Daytime PCO₂ remains elevated (increase target tidal volume by 50-100 mL increments)
• Persistent nocturnal hypoxemia (optimize EPAP, consider supplemental oxygen)
• High leak volumes (refit mask, consider oronasal interface)
• IPAP max frequently reached (increase IPAP max limit)

Disease-Specific Considerations

COPD: Requires PaCO₂ ≥52 mmHg for initiation; use lower %IPAP time (longer expiratory time); backup rate essential for those with recurrent acute-on-chronic respiratory failure 2, 3.

Obesity-hypoventilation syndrome: AVAPS shows superior PCO₂ reduction compared to standard bilevel in some studies, though clinical outcomes (sleep quality, quality of life) are comparable 4. Initial CPAP trial recommended; switch to AVAPS if hypercapnia persists 5.

Neuromuscular disease: AVAPS particularly beneficial given progressive muscle weakness; early implementation of ST mode recommended; close follow-up essential due to disease progression 5.

Restrictive chest wall disease: Both pressure and volume modes effective; AVAPS acceptable alternative to standard bilevel ST mode; use higher %IPAP time (longer inspiratory time) 2.

Evidence Limitations

Current evidence shows AVAPS is equally effective as standard bilevel pressure support for gas exchange, sleep quality, and quality of life in chronic respiratory failure 6, 7. One study in OHS demonstrated better PCO₂ reduction with AVAPS but no additional clinical benefit 4. No survival advantage has been demonstrated for AVAPS over bilevel 6, 7. The theoretical advantage of automatic pressure adjustment maintaining consistent ventilatory support through disease progression remains unproven in long-term outcomes 6.